Maternal serum ADAM-12 as a potential marker for different adverse pregnancy outcomes

Fetal Diagnosis and Therapy

Volumn 27, Issue 1, 2010, Pages 32-39

  Matwejew, E ^a   Cowans, N J ^b   Stamatopoulou, A ^b   Spencer, K ^b   Von Kaisenberg, C S ^a,c  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b KING GEORGE HOSPITAL   (United Kingdom)

^c HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Adverse outcome; First trimester; HELLP; Pre eclampsia; Screening; Small for gestational age

Indexed keywords

ADAM PROTEIN; PROTEIN ADAM 12; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; FEMALE; FIRST TRIMESTER PREGNANCY; GESTATIONAL AGE; HELLP SYNDROME; HUMAN; MAJOR CLINICAL STUDY; MATERNAL HYPERTENSION; PREECLAMPSIA; PREGNANCY OUTCOME; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SMALL FOR DATE INFANT; SMOKING;

ADAM PROTEINS; ADULT; BIOLOGICAL MARKERS; FEMALE; GESTATIONAL AGE; HUMANS; MEMBRANE PROTEINS; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME;

EID: 76449102361     PISSN: 10153837     EISSN: None     Source Type: Journal    
DOI: 10.1159/000275669     Document Type: Article

References (40)

1. Barker DJ, Gluckman PD, Godfrey KM, Harding JE, Owens JA, Robinson JS: Fetal nutrition and cardiovascular disease in adult life. Lancet 1993; 341: 938-941.
2. Curtin WM, Weinstein L: A review of HELLP syndrome. J Perinatol 1999; 19: 138-143.
3. Dekker G, Sibai B: Primary, secondary, and tertiary prevention of pre-eclampsia. Lancet 2001; 357: 209-215.
4. Mihu D, Costin N, Mihu CM, Seicean A, Ciortea R: HELLP syndrome - a multisystemic disorder. J Gastrointest Liver Dis 2007; 16: 419-424.
5. Roberts JM, Cooper DW: Pathogenesis and genetics of pre-eclampsia. Lancet 2001; 357: 53-56.
6. Sibai B, Dekker G, Kupferminc M: Pre-eclampsia. Lancet 2005; 365: 785-799.
7. Sibai BM, Ramadan MK: Acute renal failure in pregnancies complicated by hemolysis, elevated liver enzymes, and low platelets. Am J Obstet Gynecol 1993; 168: 1682-1687.
8. Weinstein L: Syndrome of hemolysis, elevated liver enzymes, and low platelet count: a severe consequence of hypertension in pregnancy. Am J Obstet Gynecol 1982; 142: 159-167.
9. Duley L, Henderson-Smart DJ, Meher S, King JF: Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev 2007;CD004659.
10. Hayman R: Hypertension in pregnancy. Curr Obstet Gynaecol 2004; 14: 1-10.
11. Walker JJ: Pre-eclampsia. Lancet 2000; 356: 1260-1265.
12. Papageorghiou AT, Yu CK, Nicolaides KH: The role of uterine artery Doppler in predicting adverse pregnancy outcome. Best Pract Res Clin Obstet Gynaecol 2004; 18: 383-396.
13. Spencer K, Yu CK, Cowans NJ, Otigbah C, Nicolaides KH: Prediction of pregnancy complications by first-trimester maternal serum PAPP-A and free-hCG and with second- trimester uterine artery Doppler. Prenat Diagn 2005; 25: 949-953.
14. Spencer K, Cowans NJ, Chefetz I, Tal J, Kuhnreich I, Meiri H: Second-trimester uterine artery Doppler pulsatility index and maternal serum PP13 as markers of preeclampsia. Prenat Diagn 2007; 27: 258-263. (Pubitemid 46450585)
15. Spencer K, Cowans NJ, Nicolaides KH: Maternal serum inhibin-A and activin-A levels in the first trimester of pregnancies developing pre-eclampsia. Ultrasound Obstet Gynecol 2008; 32: 622-626.
16. Loechel F, Gilpin BJ, Engvall E, Albrechtsen R, Wewer UM: Human ADAM-12 (meltrin) is an active metalloprotease. J Biol Chem 1998; 273: 16993-16997.
17. Loechel F, Fox JW, Murphy G, Albrechtsen R, Wewer UM: ADAM-12-S cleaves IGFBP-3 and IGFBP-5 and is inhibited by TIMP-3. Biochem Biophys Res Commun 2000; 278: 511-515.
18. Shi Z, Xu W, Loechel F, Wewer UM, Murphy LJ: ADAM-12, a disintegrin metalloprotease, interacts with insulin-like growth factorbinding protein-3. J Biol Chem 2000; 275: 18574-18580.
19. Laigaard J, Sorensen T, Frohlich C, Pedersen BN, Christiansen M, Schiott K, Uldbjerg N, Albrechtsen R, Clausen HV, Ottesen B, Wewer UM: ADAM-12: a novel first-trimester maternal serum marker for Down syndrome. Prenat Diagn 2003; 23: 1086-1091.
20. Laigaard J, Christiansen M, Frohlich C, Pedersen BN, Ottesen B, Wewer UM: The level of ADAM-12-S in maternal serum is an early first-trimester marker of fetal trisomy-18. Prenat Diagn 2005; 25: 45-46.
21. Laigaard J, Cuckle H, Wewer UM, Christiansen M: Maternal serum ADAM-12 levels in Down and Edwards' syndrome pregnancies at 9-12 weeks' gestation. Prenat Diagn 2006; 26: 689-691.
22. Laigaard J, Spencer K, Christiansen M, Cowans NJ, Larsen SO, Pedersen BN, Wewer UM: ADAM-12 as a first-trimester maternal serum marker in screening for Down syndrome. Prenat Diagn 2006; 26: 973-979. (Pubitemid 44671051)
23. Spencer K, Cowans NJ, Stamatopoulou A: Maternal serum ADAM-12s as a marker of rare aneuploidies in the first or second trimester of pregnancy. Prenat Diagn 2007; 27: 1233-1237.
24. Spencer K, Cowans NJ, Uldbjerg N, Torring N: First-trimester ADAM-12s as early markers of trisomy-21: a promise still unfulfilled? Prenat Diagn 2008; 28: 338-342.
25. Spencer K, Vereecken A, Cowans NJ: Maternal serum ADAM-12s as a potential marker of trisomy-21 prior to 10 weeks of gestation. Prenat Diagn 2008; 28: 209-211.
26. Christiansen M, Spencer K, Laigaard J, Cowans NJ, Larsen SO, Wewer UM: ADAM-12 as a second-trimester maternal serum marker in screening for Down syndrome. Prenat Diagn 2007; 27: 611-615. (Pubitemid 47121587)
27. Donalson K, Turner S, Wastell H, Cuckle H: Second-trimester maternal serum ADAM- levels in Down's syndrome pregnancies. Prenat Diagn 2008; 28: 904-907.
28. Laigaard J, Sorensen T, Placing S, Holck P, Frohlich C, Wojdemann KR, Sundberg K, Shalmi AC, Tabor A, Norgaard-Pedersen B, Ottesen B, Christiansen M, Wewer UM: Reduction of the disintegrin and metalloprotease ADAM-12 in preeclampsia. Obstet Gynecol 2005; 106: 144-149.
29. Spencer K, Cowans NJ, Stamatopoulou A: ADAM-12s in maternal serum as a potential marker of pre-eclampsia. Prenat Diagn 2008; 28: 212-216.
30. Cowans NJ, Spencer K: First-trimester ADAM-12 and PAPP-A as markers for intrauterine fetal growth restriction through their roles in the insulin-like growth factor system. Prenat Diagn 2007; 27: 264-271.
31. Pihl K, Larsen T, Krebs L, Christiansen M: First-trimester maternal serum PAPP-A, - hCG and ADAM-12 in prediction of smallfor- gestational-age fetuses. Prenat Diagn 2008; 28: 1131-1135.
32. Poon LC, Chelemen T, Granvillano O, Pandeva I, Nicolaides KH: First-trimester maternal serum a disintegrin and metalloprotease 12 (ADAM-12) and adverse pregnancy outcome. Obstet Gynecol 2008; 112: 1082-1090.
33. Cowans NJ, Stamatopoulou A, Matwejew E, von Kaisenberg C, Spencer K: First-trimester placenta growth factor (PlGF) as a potential marker for different hypertensive disorders and IUGR. 2009 (submitted).
34. Stamatopoulou A, Cowans NJ, Matwejew E, von Kaisenberg C, Spencer K: Placental protein-13 and pregnancy associated plasma protein-A as first-trimester screening markers for hypertensive disorders and IUGR. 2009 (submitted).
35. Davey DA, MacGillivray I: The classification and definition of the hypertensive disorders of pregnancy. Am J Obstet Gynecol 1988; 158: 892-898.
36. Marsal K, Persson PH, Larsen T, Lilja H, Selbing A, Sultan B: Intrauterine growth curves based on ultrasonically estimated foetal weights. Acta Paediatr 1996; 85: 843-848.
37. Spencer K, Bindra R, Nicolaides KH: Maternal weight correction of maternal serum PAPP-A and free-hCG MoM when screening for trisomy-21 in the first trimester of pregnancy. Prenat Diagn 2003; 23: 851-855.
38. Makrydimas G, Sotiriadis A, Spencer K, Cowans NJ, Nicolaides KH: ADAM-12s in coelomic fluid and maternal serum in early pregnancy. Prenat Diagn 2006; 26: 1197-1200.
39. Gack S, Marme A, Marme F, Wrobel G, Vonderstrass B, Bastert G, Lichter P, Angel P, Schorpp-Kistner M: Preeclampsia: increased expression of soluble ADAM-12. J Mol Med 2005; 83: 887-896.
40. Spencer K, Cowans NJ: ADAM-12 as a marker of trisomy-18 in the first and second trimester of pregnancy. J Matern Fetal Neonatal Med 2007; 20: 645-650.